Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free PYXS Stock Alerts

Pyxis Oncology (PYXS) Financials

Pyxis Oncology logo
$2.64 -0.05 (-1.86%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$2.60 -0.04 (-1.67%)
As of 07/9/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Pyxis Oncology

Annual Income Statements for Pyxis Oncology

This table shows Pyxis Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -76 -121 -74 -77 -80
Consolidated Net Income / (Loss)		 -13 -76 -121 -74 -77 -80
Net Income / (Loss) Continuing Operations		 -13 -76 -121 -74 -77 -80
Total Pre-Tax Income 		-13 -76 -121 -74 -79 -78
Total Operating Income		 -13 -70 -123 -82 -89 -84
Total Gross Profit		 0.00 0.00 0.00 1.78 16 11
Total Revenue		 0.00 0.00 0.00 1.78 16 14
Operating Revenue		 - - 0.00 1.78 16 14
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.48 2.39
Operating Cost of Revenue		 - - - 0.00 0.48 2.39
Total Operating Expenses		 13 70 123 82 105 96
Selling, General & Admin Expense		 3.85 19 37 33 25 22
Research & Development Expense		 9.05 51 86 50 59 74
Impairment Charge		 - - - 0.00 21 0.00
Total Other Income / (Expense), net		 0.07 -6.03 2.76 8.41 9.97 6.19
Interest & Investment Income		 0.07 0.02 2.76 6.63 7.04 3.61
Other Income / (Expense), net		 0.00 -6.05 - - 2.93 2.58
Income Tax Expense		 - - - 0.00 -2.16 1.39
Basic Earnings per Share		 ($12.45) ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Weighted Average Basic Shares Outstanding		 1.03M 8.49M 33.03M 39.90M 58.45M 62.14M
Diluted Earnings per Share		 ($12.45) ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Weighted Average Diluted Shares Outstanding		 1.03M 8.49M 33.03M 39.90M 58.45M 62.14M
Weighted Average Basic & Diluted Shares Outstanding		 1.03M 8.49M 36.98M 58.13M 61.59M 62.83M

Quarterly Income Statements for Pyxis Oncology

This table shows Pyxis Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -15 -3.38 -17 -21 -36 -21 -18 -22 -18 -23
Consolidated Net Income / (Loss)		 -23 -16 -3.26 -17 -21 -36 -21 -18 -22 -18 -23
Net Income / (Loss) Continuing Operations		 -23 -16 -3.26 -17 -21 -36 -21 -18 -22 -18 -23
Total Pre-Tax Income 		-23 -16 -3.26 -17 -21 -38 -21 -18 -22 -17 -23
Total Operating Income		 -25 -18 -5.61 -20 -24 -40 -23 -20 -23 -18 -24
Total Gross Profit		 0.60 0.58 16 0.71 0.71 -2.21 0.52 3.50 0.68 6.77 0.63
Total Revenue		 0.60 0.58 17 0.71 0.71 -2.21 0.52 3.50 0.68 9.16 0.63
Operating Revenue		 0.60 0.58 17 0.71 0.71 -2.21 0.52 3.50 0.68 9.16 0.63
Total Cost of Revenue		 0.00 - 0.48 0.00 0.00 - 0.00 0.00 0.00 2.39 0.00
Total Operating Expenses		 25 18 21 20 24 40 23 23 23 27 24
Selling, General & Admin Expense		 11 6.16 8.25 6.08 6.01 5.08 5.87 5.44 5.65 5.23 4.38
Research & Development Expense		 15 12 13 14 18 14 17 17 18 22 20
Total Other Income / (Expense), net		 2.31 2.17 2.35 2.73 2.55 2.33 1.76 1.68 1.46 1.29 1.09
Interest & Investment Income		 1.71 1.59 1.55 2.02 1.85 1.62 1.24 1.00 0.77 0.60 0.46
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.02 -0.17 0.12 0.04 -0.45 - 0.12 0.05 -0.07 - 0.05
Basic Earnings per Share		 ($0.56) ($0.34) ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37)
Weighted Average Basic Shares Outstanding		 41.33M 39.90M 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M
Diluted Earnings per Share		 ($0.56) ($0.34) ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37)
Weighted Average Diluted Shares Outstanding		 41.33M 39.90M 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M
Weighted Average Basic & Diluted Shares Outstanding		 - 58.13M 58.89M 58.94M 59.47M 61.59M 61.95M 62.02M 62.26M 62.83M 63.36M

Annual Cash Flow Statements for Pyxis Oncology

This table details how cash moves in and out of Pyxis Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -12 268 -96 -170 9.81 -4.05
Net Cash From Operating Activities		 -10 -35 -89 -71 -58 -64
Net Cash From Continuing Operating Activities		 -10 -35 -89 -71 -58 -64
Net Income / (Loss) Continuing Operations		 -13 -76 -121 -74 -77 -80
Consolidated Net Income / (Loss)		 -13 -76 -121 -74 -77 -80
Depreciation Expense		 0.47 0.65 0.71 1.93 2.98 4.51
Amortization Expense		 - - 0.00 -4.79 -6.11 -2.96
Non-Cash Adjustments To Reconcile Net Income		 0.41 33 26 18 35 13
Changes in Operating Assets and Liabilities, net		 1.87 6.68 4.50 -12 -12 1.94
Net Cash From Investing Activities		 -1.48 -0.59 -6.40 -105 8.16 59
Net Cash From Continuing Investing Activities		 -1.48 -0.59 -6.40 -105 8.16 59
Purchase of Property, Plant & Equipment		 -1.48 -0.54 -6.40 -6.73 -0.24 -0.01
Acquisitions		 0.00 -0.05 0.00 0.00 0.00 0.00
Purchase of Investments		 - - 0.00 -197 -160 -107
Divestitures		 - - 0.00 6.66 0.00 0.00
Sale and/or Maturity of Investments		 - - 0.00 92 169 166
Net Cash From Financing Activities		 0.04 304 0.18 5.93 59 0.59
Net Cash From Continuing Financing Activities		 0.04 304 0.18 5.93 59 0.59
Issuance of Preferred Equity		 0.00 152 0.00 0.00 0.00 0.00
Issuance of Common Equity		 0.00 152 0.00 6.25 59 0.11
Other Financing Activities, net		 0.03 0.17 0.18 -0.33 0.06 0.48
Cash Interest Paid		 - - - 0.00 0.01 0.09
Cash Interest Received		 - 0.00 2.17 0.00 0.00 0.00
Cash Income Taxes Paid		 - 0.00 0.02 0.05 0.16 1.38

Quarterly Cash Flow Statements for Pyxis Oncology

This table details how cash moves in and out of Pyxis Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -5.05 18 -2.89 -13 7.42 -6.71 -2.03 -1.81 6.50 -9.66
Net Cash From Operating Activities		 -15 -21 -3.01 -15 -19 -23 -17 -13 -10 -26
Net Cash From Continuing Operating Activities		 -15 -21 -3.01 -15 -19 -23 -17 -13 -10 -26
Net Income / (Loss) Continuing Operations		 -16 -3.26 -17 -21 -36 -21 -18 -22 -18 -23
Consolidated Net Income / (Loss)		 -16 -3.26 -17 -21 -36 -21 -18 -22 -18 -23
Depreciation Expense		 0.69 1.12 0.59 0.73 0.55 0.55 0.54 0.53 2.90 0.46
Amortization Expense		 -1.44 -1.29 -1.64 -1.65 -1.53 -1.16 -0.90 -0.53 -0.38 -0.24
Non-Cash Adjustments To Reconcile Net Income		 0.71 4.48 3.04 3.16 24 3.82 3.22 3.28 2.30 1.44
Changes in Operating Assets and Liabilities, net		 0.39 -22 12 4.30 -6.66 -4.60 -1.77 5.45 2.86 -4.39
Net Cash From Investing Activities		 10 -18 0.00 -0.01 27 16 15 11 16 16
Net Cash From Continuing Investing Activities		 10 -18 0.00 -0.01 27 16 15 11 16 16
Purchase of Property, Plant & Equipment		 - -0.24 - - - 0.00 - -0.01 - 0.00
Purchase of Investments		 -10 -93 -39 -24 -4.37 -51 -41 -15 - -11
Divestitures		 0.00 0.00 - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 20 75 39 24 31 67 56 26 16 27
Net Cash From Financing Activities		 -0.03 58 0.11 1.66 0.05 0.00 -0.07 -0.01 0.67 -0.03
Net Cash From Continuing Financing Activities		 -0.03 58 0.11 1.66 0.05 0.00 -0.07 -0.01 0.67 -0.03
Issuance of Common Equity		 0.03 57 0.11 1.66 0.05 0.00 - - 0.11 0.00
Other Financing Activities, net		 -0.05 0.05 0.01 -0.00 0.00 -0.00 -0.07 -0.01 0.56 -0.03

Annual Balance Sheets for Pyxis Oncology

This table presents Pyxis Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 10 280 211 174 157 92
Total Current Assets		 8.10 279 187 125 132 72
Cash & Equivalents		 8.08 275 179 9.66 19 15
Restricted Cash		 - 1.47 1.47 1.47 1.47 1.47
Short-Term Investments		 - - 0.00 110 107 51
Prepaid Expenses		 0.02 2.47 5.85 3.83 4.04 3.78
Plant, Property, & Equipment, net		 1.10 1.01 11 12 9.90 8.00
Total Noncurrent Assets		 0.95 0.34 14 37 15 11
Intangible Assets		 - - 0.00 24 2.60 0.00
Other Noncurrent Operating Assets		 0.95 0.34 14 13 12 11
Total Liabilities & Shareholders' Equity		 10 280 211 174 157 92
Total Liabilities		 3.85 19 51 48 36 38
Total Current Liabilities		 3.69 19 32 26 18 21
Accounts Payable		 1.08 12 7.10 3.90 4.86 11
Accrued Expenses		 2.00 6.59 25 13 11 8.55
Other Current Liabilities		 0.62 0.17 0.00 1.23 1.45 1.69
Total Noncurrent Liabilities		 0.17 0.00 19 22 19 17
Capital Lease Obligations		 - - - 0.00 0.10 0.02
Other Noncurrent Operating Liabilities		 0.17 0.00 19 20 19 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 261 161 126 121 53
Total Preferred & Common Equity		 -16 261 161 126 121 53
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -16 261 161 126 121 53
Common Stock		 0.10 353 373 412 484 497
Retained Earnings		 -16 -92 -212 -286 -364 -443
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.06 0.17 0.05

Quarterly Balance Sheets for Pyxis Oncology

This table presents Pyxis Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 187 220 208 195 136 123 106 64
Total Current Assets		 139 172 161 149 112 100 83 46
Cash & Equivalents		 15 28 25 12 13 11 8.92 5.77
Restricted Cash		 1.47 1.47 1.47 1.47 1.47 1.47 1.47 1.47
Short-Term Investments		 118 129 131 133 93 78 67 35
Prepaid Expenses		 4.66 5.88 3.84 2.58 4.97 6.54 5.35 3.08
Plant, Property, & Equipment, net		 12 11 11 10 9.40 8.92 8.46 7.54
Total Noncurrent Assets		 35 37 36 36 15 14 14 11
Intangible Assets		 22 24 24 24 2.54 2.49 2.43 0.00
Other Noncurrent Operating Assets		 13 13 13 12 12 12 12 11
Total Liabilities & Shareholders' Equity		 187 220 208 195 136 123 106 64
Total Liabilities		 49 36 39 42 33 36 37 33
Total Current Liabilities		 28 14 17 20 14 18 19 17
Accounts Payable		 3.31 2.29 5.47 4.87 2.85 9.41 9.76 4.99
Accrued Expenses		 17 11 10 14 10 6.70 8.00 9.79
Other Current Liabilities		 1.20 1.02 1.34 1.39 1.51 1.57 1.63 1.76
Total Noncurrent Liabilities		 20 22 22 21 18 18 17 17
Capital Lease Obligations		 - - 0.14 0.12 0.08 0.06 0.04 0.00
Other Noncurrent Operating Liabilities		 20 20 19 19 18 18 17 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 138 184 170 154 103 88 69 31
Total Preferred & Common Equity		 138 184 170 154 103 88 69 31
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 138 184 170 154 103 88 69 31
Common Stock		 409 474 477 481 488 491 494 498
Retained Earnings		 -271 -289 -307 -328 -385 -403 -425 -466
Accumulated Other Comprehensive Income / (Loss)		 -0.11 -0.06 -0.10 0.35 0.05 -0.01 0.07 0.00

Annual Metrics And Ratios for Pyxis Oncology

This table displays calculated financial ratios and metrics derived from Pyxis Oncology's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 32,763,887.00 35,097,256.00 44,323,046.00 59,465,729.00 62,264,215.00
DEI Adjusted Shares Outstanding		 0.00 32,763,887.00 35,097,256.00 44,323,046.00 59,465,729.00 62,264,215.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.32 -3.44 -1.66 -1.30 -1.28
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 809.12% -14.17%
EBITDA Growth		 0.00% -504.59% -64.38% 31.12% -5.41% 10.45%
EBIT Growth		 0.00% -487.61% -62.97% 33.43% -5.28% 5.42%
NOPAT Growth		 0.00% -440.69% -77.12% 33.43% -8.84% 5.63%
Net Income Growth		 0.00% -492.26% -58.89% 38.87% -4.80% -2.96%
EPS Growth		 0.00% 28.11% 59.22% 49.32% 28.65% 3.03%
Operating Cash Flow Growth		 0.00% -250.32% 0.00% 20.85% 18.44% -10.11%
Free Cash Flow Firm Growth		 0.00% 0.00% -128.04% -1.26% 39.16% -3.22%
Invested Capital Growth		 0.00% -735.33% -33.89% 124.74% -253.06% -97.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -14.72% 155.82%
EBITDA Q/Q Growth		 0.00% 0.00% -21.95% 0.00% -27.99% 25.76%
EBIT Q/Q Growth		 0.00% 0.00% -21.14% 0.00% -28.85% 22.93%
NOPAT Q/Q Growth		 0.00% 0.00% -21.14% 0.00% -33.21% 20.50%
Net Income Q/Q Growth		 0.00% 0.00% -19.00% 0.00% -34.82% 17.99%
EPS Q/Q Growth		 0.00% 0.00% -112.09% 0.00% -26.92% 20.99%
Operating Cash Flow Q/Q Growth		 0.00% -34.20% 0.00% 2.93% -7.52% 12.25%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 10.66%
Invested Capital Q/Q Growth		 0.00% 0.00% -77.05% 0.00% -200.60% -67.28%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 97.06% 82.77%
EBITDA Margin		 0.00% 0.00% 0.00% -4,789.25% -555.31% -579.41%
Operating Margin		 0.00% 0.00% 0.00% -4,628.15% -554.07% -609.18%
EBIT Margin		 0.00% 0.00% 0.00% -4,628.15% -535.95% -590.60%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -4,154.84% -478.95% -574.55%
Tax Burden Percent		 100.00% 100.31% 100.00% 100.00% 97.28% 101.77%
Interest Burden Percent		 99.49% 99.97% 97.76% 89.77% 91.87% 95.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -203.72% -56.78% -57.19% -51.51% -62.75% -91.43%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,670.29% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -42.69% -52.30% -65.82%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -38.32% -46.74% -64.03%
Return on Common Equity (ROCE)		 506.14% -52.12% -57.19% -51.51% -62.75% -91.43%
Return on Equity Simple (ROE_SIMPLE)		 81.99% -29.07% -75.06% -58.70% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.03 -49 -86 -58 -63 -59
NOPAT Margin		 0.00% 0.00% 0.00% -3,239.71% -387.85% -426.43%
Net Nonoperating Expense Percent (NNEP)		 -47.06% -19.12% -15.00% -10.78% -11.81% -20.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - -53.75% -45.77% -51.82% -110.60%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 2.94% 17.23%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 1,836.15% 157.44% 160.15%
R&D to Revenue		 0.00% 0.00% 0.00% 2,792.00% 363.85% 531.79%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 4,628.15% 651.13% 691.95%
Earnings before Interest and Taxes (EBIT)		 -13 -76 -123 -82 -87 -82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -75 -123 -85 -90 -80
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.36 0.28 0.57 0.76 1.34
Price to Tangible Book Value (P/TBV)		 0.00 0.36 0.28 0.71 0.77 1.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 40.44 5.65 5.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.28 -1.06 -1.08 -1.05 -1.01 -1.13
Leverage Ratio		 1.61 1.08 1.16 1.34 1.34 1.43
Compound Leverage Factor		 1.60 1.08 1.14 1.21 1.23 1.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.08% 0.04%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.08% 0.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 348.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -248.45% 100.00% 100.00% 100.00% 99.92% 99.96%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 1.43 0.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 2.05 1.16
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 20.31 2.75 -1.93 -2.28 -2.57 -7.79
Noncontrolling Interest Sharing Ratio		 348.45% 8.20% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 2.20 14.90 5.90 4.84 7.49 3.41
Quick Ratio		 2.19 14.69 5.67 4.63 7.18 3.16
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -36 -81 -82 -50 -52
Operating Cash Flow to CapEx		 -679.97% -6,541.85% 0.00% -1,051.28% -24,334.18% -705,577.78%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.10 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.15 1.48 1.55
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.11 0.30
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 3,363.76 1,203.22
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -3,363.76 -1,203.22
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.78 -15 -20 4.93 -7.55 -15
Invested Capital Turnover		 0.00 0.00 0.00 -0.24 -12.33 -1.23
Increase / (Decrease) in Invested Capital		 0.00 -13 -5.05 25 -12 -7.35
Enterprise Value (EV)		 182 -183 -137 -49 -37 3.16
Market Capitalization		 168 93 44 72 91 71
Book Value per Share		 ($15.18) $7.98 $4.58 $2.84 $2.03 $0.86
Tangible Book Value per Share		 ($15.18) $7.98 $4.58 $2.29 $1.99 $0.86
Total Capital		 6.30 261 161 126 121 53
Total Debt		 0.00 0.00 0.00 0.00 0.10 0.02
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.10 0.02
Net Debt		 -8.08 -276 -181 -121 -128 -68
Capital Expenditures (CapEx)		 1.48 0.54 0.00 6.73 0.24 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.67 -16 -26 -22 -14 -17
Debt-free Net Working Capital (DFNWC)		 4.41 260 155 99 115 51
Net Working Capital (NWC)		 4.41 260 155 99 115 51
Net Nonoperating Expense (NNE)		 3.80 27 34 16 15 21
Net Nonoperating Obligations (NNO)		 -8.08 -276 -181 -121 -128 -68
Total Depreciation and Amortization (D&A)		 0.47 0.65 0.00 -2.86 -3.13 1.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,234.52% -84.50% -125.23%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 5,565.60% 710.76% 367.83%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 5,565.60% 710.76% 367.83%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 32.84M 33.03M 39.90M 58.45M 62.14M
Adjusted Diluted Earnings per Share		 $0.00 ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 32.84M 33.03M 39.90M 58.45M 62.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.95) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.49M 36.98M 58.13M 61.59M 62.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.03 -49 -86 -58 -48 -59
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -3,239.71% -296.96% -426.43%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -4,154.84% -492.35% -564.55%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Pyxis Oncology

This table displays calculated financial ratios and metrics derived from Pyxis Oncology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 39,526,842.00 44,323,046.00 58,133,375.00 58,888,473.00 58,942,243.00 59,465,729.00 61,590,415.00 61,947,665.00 62,018,135.00 62,264,215.00 62,831,246.00
DEI Adjusted Shares Outstanding		 39,526,842.00 44,323,046.00 58,133,375.00 58,888,473.00 58,942,243.00 59,465,729.00 61,590,415.00 61,947,665.00 62,018,135.00 62,264,215.00 62,831,246.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.58 -0.35 -0.06 -0.29 -0.35 -0.60 -0.35 -0.30 -0.35 -0.29 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 44,492.11% 25.53% 17.89% -484.03% -96.96% 394.92% -2.98% 513.88% 22.52%
EBITDA Growth		 10.07% 50.99% 72.97% -11.80% 2.68% -121.69% -307.11% 4.61% 4.90% 61.58% -2.64%
EBIT Growth		 10.70% 53.21% 73.25% -10.55% 6.31% -125.52% -308.81% 1.41% 1.23% 54.34% -6.31%
NOPAT Growth		 10.70% 53.21% 73.25% -10.55% 6.31% -125.52% -308.81% 1.41% 1.23% 54.34% -6.31%
Net Income Growth		 16.71% 56.80% 83.08% -8.80% 8.01% -128.06% -549.82% -6.09% -3.77% 49.10% -9.99%
EPS Growth		 34.12% 67.31% 88.89% 29.27% 37.50% -82.35% -483.33% -3.45% 0.00% 54.84% -5.71%
Operating Cash Flow Growth		 0.00% 12.27% 22.84% 72.74% 0.00% -26.46% -8.81% -474.09% 9.46% 45.95% -15.38%
Free Cash Flow Firm Growth		 -48.73% -73.27% 9.07% -4.74% 16.81% 58.29% 147.23% 106.05% 99.96% 64.91% -171.63%
Invested Capital Growth		 0.00% 124.74% 1,811.85% 0.00% 0.00% -253.06% -114.50% -121.29% -218.64% -97.27% -201.51%
Revenue Q/Q Growth		 0.00% -3.68% 2,841.84% -95.82% -0.42% -413.76% 123.28% 580.39% -80.48% 1,238.45% -93.11%
EBITDA Q/Q Growth		 0.00% 26.96% 68.80% -264.95% -17.04% -66.37% 42.71% 14.49% -16.68% 32.78% -53.05%
EBIT Q/Q Growth		 0.00% 29.92% 68.45% -257.40% -18.58% -68.68% 42.81% 13.81% -18.79% 22.02% -33.15%
NOPAT Q/Q Growth		 0.00% 29.92% 68.45% -257.40% -18.58% -68.68% 42.81% 13.81% -18.79% 22.02% -33.15%
Net Income Q/Q Growth		 0.00% 32.33% 79.12% -431.36% -22.55% -67.76% 40.52% 13.25% -19.88% 17.71% -28.53%
EPS Q/Q Growth		 0.00% 39.29% 82.35% -383.33% -20.69% -77.14% 43.55% 14.29% -16.67% 20.00% -32.14%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -35.77% 85.48% -387.70% -31.54% -16.82% 23.39% 23.09% 21.47% -149.35%
Free Cash Flow Firm Q/Q Growth		 0.00% -28.61% 24.32% 5.25% 9.79% 35.52% 185.71% -87.86% -100.60% -56,193.81% -74.97%
Invested Capital Q/Q Growth		 0.00% 0.00% 420.00% -50.37% -41.04% -200.60% 50.73% 27.14% -228.51% -67.28% 24.69%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 97.20% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 73.92% 100.00%
EBITDA Margin		 -4,239.80% -3,214.93% -34.09% -2,977.82% -3,500.00% 0.00% -4,566.80% -573.94% -3,430.70% -172.29% -3,825.67%
Operating Margin		 -4,239.80% -3,084.55% -33.08% -2,829.38% -3,369.36% 0.00% -4,449.32% -563.64% -3,429.97% -199.84% -3,860.54%
EBIT Margin		 -4,239.80% -3,084.55% -33.08% -2,829.38% -3,369.36% 0.00% -4,449.32% -563.64% -3,429.97% -199.84% -3,860.54%
Profit (Net Income) Margin		 -3,854.35% -2,707.81% -19.22% -2,443.64% -3,007.52% 0.00% -4,108.35% -523.80% -3,216.81% -197.77% -3,688.11%
Tax Burden Percent		 100.00% 100.24% 100.00% 100.00% 100.00% 94.27% 100.00% 101.57% 100.00% 106.49% 100.00%
Interest Burden Percent		 90.91% 87.57% 58.09% 86.37% 89.26% 94.18% 92.34% 91.50% 93.79% 92.94% 95.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -32.05% -5,856.92% -11,897.39% 0.00% 0.00% -428.17% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -32.48% -5,852.75% -11,891.13% 0.00% 0.00% -424.51% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 29.87% 2,917.58% 5,960.24% 0.00% 0.00% 407.98% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -51.51% -2.18% -2,939.34% -5,937.14% -62.75% -66.30% -20.19% -87.28% -91.43% -121.66%
Cash Return on Invested Capital (CROIC)		 0.00% -1,670.29% -526.74% -956.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -28.45% -3.07% -277.72% -334.01% 0.00% 0.00% -18.49% -123.49% -22.27% -539.02%
Return on Assets (ROA)		 0.00% -24.98% -1.78% -239.86% -298.14% 0.00% 0.00% -17.18% -115.82% -22.04% -514.95%
Return on Common Equity (ROCE)		 0.00% -51.51% -2.18% -2,939.34% -5,937.14% -62.75% -66.30% -20.19% -87.28% -91.43% -121.66%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -31.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -12 -3.92 -14 -17 -28 -16 -14 -16 -13 -17
NOPAT Margin		 -2,967.86% -2,159.18% -23.15% -1,980.57% -2,358.55% 0.00% -3,114.52% -394.55% -2,400.98% -139.89% -2,702.38%
Net Nonoperating Expense Percent (NNEP)		 0.00% -2.10% 0.43% -4.17% -6.26% -6.04% -3.86% -3.66% -4.99% -5.39% -8.33%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.89% -2.13% -8.25% -10.81% -23.21% -15.55% -15.76% -23.86% -23.97% -54.53%
Cost of Revenue to Revenue		 0.00% 0.00% 2.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.08% 0.00%
SG&A Expenses to Revenue		 1,783.78% 1,069.44% 48.67% 858.62% 852.91% 0.00% 1,139.81% 155.17% 826.46% 57.17% 693.66%
R&D to Revenue		 2,456.02% 2,015.10% 76.89% 1,970.76% 2,516.45% 0.00% 3,309.51% 488.96% 2,603.51% 237.15% 3,166.88%
Operating Expenses to Revenue		 4,239.80% 3,084.55% 125.56% 2,829.38% 3,369.36% 0.00% 4,449.32% 644.12% 3,429.97% 294.32% 3,860.54%
Earnings before Interest and Taxes (EBIT)		 -25 -18 -5.61 -20 -24 -40 -23 -20 -23 -18 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -19 -5.78 -21 -25 -41 -24 -20 -23 -16 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.57 1.19 1.18 1.45 0.76 0.58 0.78 2.02 1.34 2.96
Price to Tangible Book Value (P/TBV)		 0.00 0.71 1.36 1.37 1.71 0.77 0.59 0.80 2.09 1.34 2.96
Price to Revenue (P/Rev)		 0.00 40.44 11.69 10.64 11.77 5.65 0.00 12.53 25.64 5.16 6.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 2.34 3.39 10.21 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 3.21 2.29 4.05 0.00 0.00 0.00 11.30 0.23 3.59
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.05 -0.92 -0.50 -0.50 -1.01 -0.92 -0.96 -1.01 -1.13 -1.11
Leverage Ratio		 0.00 1.34 1.20 1.22 1.31 1.34 1.24 1.29 1.35 1.43 1.49
Compound Leverage Factor		 0.00 1.18 0.70 1.05 1.17 1.26 1.14 1.18 1.27 1.33 1.42
Debt to Total Capital		 0.00% 0.00% 0.00% 0.08% 0.08% 0.08% 0.08% 0.07% 0.06% 0.04% 0.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.08% 0.08% 0.08% 0.08% 0.07% 0.06% 0.04% 0.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 99.92% 99.92% 99.92% 99.92% 99.93% 99.94% 99.96% 99.99%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 2.19 2.09 1.43 0.97 0.83 0.72 0.85 0.51
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 3.26 3.11 2.05 1.43 1.21 1.05 1.16 0.71
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -1.05 2.66 1.66 1.35 -1.60 -2.57 -3.11 -3.33 -5.49 -8.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 4.84 12.19 9.53 7.33 7.49 7.75 5.65 4.29 3.41 2.76
Quick Ratio		 0.00 4.63 11.67 9.22 7.13 7.18 7.31 5.20 3.93 3.16 2.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -37 -28 -27 -24 -16 13 1.62 -0.01 -5.46 -9.55
Operating Cash Flow to CapEx		 0.00% 0.00% -8,738.40% 0.00% 0.00% 0.00% 0.00% 0.00% -147,522.22% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.09 0.10 0.10 0.10 0.00 0.03 0.04 0.11 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.15 1.53 1.59 1.68 1.48 0.00 0.54 0.57 1.55 1.65
Accounts Payable Turnover		 0.00 0.00 0.15 0.14 0.12 0.11 0.00 0.00 0.00 0.30 0.61
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 2,427.44 2,603.03 3,142.84 3,363.76 0.00 0.00 0.00 1,203.22 598.78
Cash Conversion Cycle (CCC)		 0.00 0.00 -2,427.44 -2,603.03 -3,142.84 -3,363.76 0.00 0.00 0.00 -1,203.22 -598.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 4.93 26 13 7.51 -7.55 -3.72 -2.71 -8.91 -15 -11
Invested Capital Turnover		 0.00 -0.24 1.38 2.96 5.04 -12.33 0.00 1.09 -7.74 -1.23 -1.87
Increase / (Decrease) in Invested Capital		 11 25 24 13 7.51 -12 -29 -15 -16 -7.35 -7.50
Enterprise Value (EV)		 0.00 -49 60 43 77 -37 -47 -22 61 3.16 50
Market Capitalization		 82 72 218 200 223 91 60 68 139 71 93
Book Value per Share		 $0.00 $2.84 $3.17 $2.88 $2.61 $2.03 $1.67 $1.41 $1.11 $0.86 $0.50
Tangible Book Value per Share		 $0.00 $2.29 $2.76 $2.48 $2.21 $1.99 $1.63 $1.37 $1.07 $0.86 $0.50
Total Capital		 0.00 126 184 170 154 121 103 88 69 53 31
Total Debt		 0.00 0.00 0.00 0.14 0.12 0.10 0.08 0.06 0.04 0.02 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.14 0.12 0.10 0.08 0.06 0.04 0.02 0.00
Net Debt		 0.00 -121 -158 -157 -146 -128 -107 -90 -78 -68 -42
Capital Expenditures (CapEx)		 0.00 0.00 0.24 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -22 -0.26 -13 -18 -14 -9.46 -8.14 -14 -17 -13
Debt-free Net Working Capital (DFNWC)		 0.00 99 158 144 129 115 97 82 64 51 29
Net Working Capital (NWC)		 0.00 99 158 144 129 115 97 82 64 51 29
Net Nonoperating Expense (NNE)		 5.30 3.16 -0.67 3.28 4.58 7.52 5.12 4.53 5.58 5.30 6.22
Net Nonoperating Obligations (NNO)		 0.00 -121 -158 -157 -146 -128 -107 -90 -78 -68 -42
Total Depreciation and Amortization (D&A)		 0.00 -0.75 -0.17 -1.05 -0.92 -0.98 -0.61 -0.36 -0.01 2.52 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,234.52% -1.40% -69.34% -93.70% -84.50% 0.00% -149.65% -259.13% -125.23% -96.25%
Debt-free Net Working Capital to Revenue		 0.00% 5,565.60% 846.96% 765.61% 678.93% 710.76% 0.00% 1,513.02% 1,175.76% 367.83% 207.81%
Net Working Capital to Revenue		 0.00% 5,565.60% 846.96% 765.61% 678.93% 710.76% 0.00% 1,513.02% 1,175.76% 367.83% 207.81%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.34) ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 39.90M 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M
Adjusted Diluted Earnings per Share		 $0.00 ($0.34) ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 39.90M 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 58.13M 58.89M 58.94M 59.47M 61.59M 61.95M 62.02M 62.26M 62.83M 63.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -12 -3.92 -14 -17 -28 -16 -14 -16 -13 -17
Normalized NOPAT Margin		 -2,967.86% -2,159.18% -23.15% -1,980.57% -2,358.55% 0.00% -3,114.52% -394.55% -2,400.98% -139.89% -2,702.38%
Pre Tax Income Margin		 -3,854.35% -2,701.22% -19.22% -2,443.64% -3,007.52% 0.00% -4,108.35% -515.72% -3,216.81% -185.72% -3,688.11%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Pyxis Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pyxis Oncology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Pyxis Oncology's net income appears to be on an upward trend, with a most recent value of -$79.62 million in 2025, rising from -$12.83 million in 2020. The previous period was -$77.33 million in 2024. View Pyxis Oncology's forecast to see where analysts expect Pyxis Oncology to go next.

Pyxis Oncology's total operating income in 2025 was -$84.42 million, based on the following breakdown:
  • Total Gross Profit: $11.47 million
  • Total Operating Expenses: $95.89 million

Over the last 5 years, Pyxis Oncology's total revenue changed from $0.00 in 2020 to $13.86 million in 2025, a change of 1,385,800,000.0%.

Pyxis Oncology's total liabilities were at $38.11 million at the end of 2025, a 4.6% increase from 2024, and a 888.9% increase since 2020.

In the past 5 years, Pyxis Oncology's cash and equivalents has ranged from $8.08 million in 2020 to $274.74 million in 2021, and is currently $15.42 million as of their latest financial filing in 2025.

Over the last 5 years, Pyxis Oncology's book value per share changed from -15.18 in 2020 to 0.86 in 2025, a change of -105.7%.


Related Companies

Financial statements for NASDAQ:PYXS last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel